Joint Venture17 Mar 2026, 12:08 pm
Zydus and Lupin Partner for Co-marketing Innovative Semaglutide Injection in India
AI Summary
Zydus Lifesciences Ltd and Lupin Limited have entered into a Licensing and Supply Agreement to co-market an innovative Semaglutide Injection in India. This partnership aims to strengthen patient access for advanced diabetes and weight management therapies. Zydus will market the product under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™, while Lupin will market it as Semanext® and Lupin’s Livarise®. Lupin will pay Zydus upfront licensing fees and milestone payments.
Key Highlights
- Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India.
- Zydus will market the product under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™.
- Lupin will market the product under the brand names Semanext® and Lupin’s Livarise®.
- Lupin will pay Zydus upfront licensing fees and milestone payments.
- Partnership aims to strengthen patient access for advanced diabetes and weight management therapies.